

# Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With $\beta$ -Blockers

Andrea Mazzanti, MD, PhD; Deni Kukavica, MD; Alessandro Trancuccio, MD; Mirella Memmi, BSc; Raffaella Bloise, MD; Patrick Gambelli, BSc; Maira Marino, RN; Martín Ortíz-Genga, MD, PhD; Massimo Morini, DEng; Nicola Monteforte, MD; Umberto Giordano, MD; Roberto Keegan, MD, PhD; Luca Tomasi, MD; Aristides Anastasakis, MD, PhD; Andrew M. Davis, MBBS, MD; Wataru Shimizu, MD, PhD; Nico A. Blom, MD, PhD; Demetrio Julián Santiago, PhD; Carlo Napolitano, MD, PhD; Lorenzo Monserrat, MD, PhD; Silvia G. Priori, MD, PhD

 Supplemental content

**IMPORTANCE** Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) may experience life-threatening arrhythmic events (LTAEs) despite  $\beta$ -blocker treatment. Further complicating management, the role of implantable cardioverter defibrillator (ICD) in CPVT is debated.

**OBJECTIVE** To investigate the long-term outcomes of patients with *RYR2* CPVT treated with  $\beta$ -blockers only and the cost to benefit ratio of ICD.

**DESIGN, SETTINGS, AND PARTICIPANTS** This prospective cohort study conducted from January 1988 to October 2020 with a mean (SD) follow-up of 9.4 (7.5) years included patients who were referred to the Molecular Cardiology Clinics of ICS Maugeri Hospital, Pavia, Italy. Participants included consecutive patients with CPVT who were carriers of a pathogenic or likely pathogenic *RYR2* variant with long-term clinical follow-up.

**EXPOSURES** Treatment with selective and nonselective  $\beta$ -blocker only and ICD implant when indicated.

**MAIN OUTCOME AND MEASURES** The main outcome was the occurrence of the first LTAE while taking a  $\beta$ -blocker. LTAE was defined as a composite of 3 hard end points: sudden cardiac death, aborted cardiac arrest, and hemodynamically nontolerated ventricular tachycardia.

**RESULTS** The cohort included 216 patients with *RYR2* CPVT (121 of 216 female [55%], median [IQR] age 14, [9-30] years). During a mean (SD) follow-up of 9.4 (7.5) years taking  $\beta$ -blockers only, 28 of 216 patients (13%) experienced an LTAE (annual rate, 1.9%; 95% CI, 1.3-2.7). In multivariable analysis, experiencing either an LTAE (hazard ratio [HR], 3.3; 95% CI, 1.2-8.9;  $P = .02$ ) or syncope before diagnosis (HR, 4.5; 95% CI, 1.8-11.1;  $P = .001$ ) and carrying a C-terminal domain variant (HR, 18.1; 95% CI, 4.1-80.8;  $P < .001$ ) were associated with an increased LTAE risk during  $\beta$ -blocker therapy only. The risk of LTAE among those taking selective  $\beta$ -blockers vs nadolol was increased 6-fold (HR, 5.8; 95% CI, 2.1-16.3;  $P = .001$ ). Conversely, no significant difference was present between propranolol and nadolol (HR, 1.8; 95% CI, 0.4-7.3;  $P = .44$ ). An ICD was implanted in 79 of 216 patients (37%) who were followed up for a mean (SD) of 8.6 (6.3) years. At the occurrence of LTAE, ICD carriers were more likely to survive (18 of 18 [100%]) than non-ICD carriers (6 of 10 [60%];  $P = .01$ ).

**CONCLUSIONS AND RELEVANCE** In this cohort study, selective  $\beta$ -blockers were associated with a higher risk of LTAE as compared with nadolol. Independently from treatment, LTAE and syncope before diagnosis and C-terminal domain variants identified patients at higher risk of  $\beta$ -blocker failure, and the ICD was associated with reduced mortality in high-risk patients with CPVT.

JAMA Cardiol. doi:10.1001/jamacardio.2022.0219  
Published online March 30, 2022.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Silvia G. Priori, MD, PhD, Molecular Cardiology, IRCCS ICS Maugeri, Via Maugeri 10, 27100 Pavia, Italy (silvia.priori@icsmaugeri.it).

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disease characterized by fatal emotion- or exercise-induced ventricular arrhythmias.<sup>1</sup> In most patients, CPVT is secondary to variants in the *RYR2* gene, encoding for cardiac ryanodine receptor,<sup>2</sup> a crucial protein for electromechanical coupling in the heart. Findings from resting electrocardiogram (ECG) are unremarkable, resulting in diagnostic delays, thus exposing young patients to the risk of sudden cardiac death (SCD). Twenty years after identification of *RYR2* as the leading cause of CPVT,<sup>2,3</sup> management of patients remains challenging.  $\beta$ -Blockers are the centerpiece of treatment,<sup>4</sup> but critical issues persist. First, an unexpectedly high proportion of patients experience breakthrough events despite  $\beta$ -blocker therapy.<sup>5</sup> Second, procurement issues with nadolol,<sup>6</sup> the  $\beta$ -blocker of choice for patients with CPVT, call for an appraisal of the role of alternative  $\beta$ -blockers. Importantly, these issues assume relevance in the absence of evidence that other treatments (ie, flecainide or left cardiac sympathetic denervation [LCSD]) confer adequate protection against LTAE and in the light of recent data<sup>7</sup> that questioned the utility of implantable cardioverter defibrillator (ICD).<sup>4</sup> The aims of our study were to evaluate the role of selective vs nonselective  $\beta$ -blocker in LTAE reduction, to identify genetic and clinical risk factors for breakthrough LTAE with  $\beta$ -blockers treatment only, and to determine if patients with CPVT benefit from the use of an ICD.

## Methods

### Study Design and Cohort Composition

This was a longitudinal cohort study of patients with *RYR2* CPVT who were treated with  $\beta$ -blockers, referred to our attention between January 1988 and October 2020 (eTable 1 in the Supplement). CPVT was diagnosed according to the 2015 European Society of Cardiology Guidelines.<sup>4</sup> Clinical information acquired since the first visit was prospectively filed in our TRIAD registry and included demographic data, personal and family history, arrhythmic events, electrocardiographic features, and therapies. The study conformed to the principles of the Declaration of Helsinki. The study protocol was approved by the ethics committee of the IRCCS ICS Maugeri, Pavia, Italy. All patients or their legal guardians provided written informed consent to grant access to their clinical and genetic data for investigational purposes. No one received compensation or was offered any incentive for participating in this study.

### Genetic Analysis

Genetic analysis on the *RYR2* gene was performed in probands either by Sanger sequencing (ABI PRISM 330; Thermo Fisher) or next-generation sequencing (Ion Torrent Personal Genome Machine; Thermo Fisher) depending on the enrollment year. Variants were evaluated by 2 expert laboratories (IRCCS, ICS Maugeri, Pavia, Italy, and Health in Code, A Coruña, Spain) and interpreted according to current criteria.<sup>8</sup> Only variants adjudicated as pathogenic or likely pathogenic by both laboratories were included (eTable 2 in the Supplement).

## Key Points

**Question** Which factors are associated with the outcome of patients with *RYR2* catecholaminergic polymorphic ventricular tachycardia during  $\beta$ -blocker treatment?

**Findings** In this cohort study including 216 patients with *RYR2* catecholaminergic polymorphic ventricular tachycardia, symptoms prior to diagnosis, C-terminal domain *RYR2* variants, and selective  $\beta$ -blockers were associated with an increased risk of  $\beta$ -blocker failure, while the implantable cardioverter defibrillator was associated with a survival benefit in patients experiencing life-threatening arrhythmic events during  $\beta$ -blocker treatment.

**Meaning** In this study, findings suggest that clinical, genetic, and therapeutic factors may help in identifying patients at increased arrhythmic risk despite  $\beta$ -blocker treatment, and implantable cardioverter defibrillator was associated with reduced mortality in high-risk patients with catecholaminergic polymorphic ventricular tachycardia.

Carriers of known loss-of-function *RYR2* variant,<sup>9</sup> and those with variants associated with other channelopathies were excluded. Cascade screening was offered to family members following the identification of a causative variant in the proband.

For the topological characterization of missense *RYR2* variants, we defined their location according to the cryoelectron microscope-resolved atomic map of the channel<sup>10</sup> (eMethods 2 in the Supplement). To identify domains overrepresented in patients with CPVT relative to control individuals (CPVT-enriched domains), we compared the distribution of the 83 missense variants found in our cohort with the distribution of 1913 rare (allele frequency < 0.01%) missense variants obtained from the Genome Aggregation Database (gnomAD), using a published methodology.<sup>11,12</sup>

### Study End Points

The end point was the occurrence of the first life-threatening arrhythmic event (LTAE, composite of SCD, aborted cardiac arrest, or hemodynamically nontolerated ventricular tachycardia [VT]<sup>13</sup>; eMethods 1 in the Supplement) while taking  $\beta$ -blocker therapy only. The follow-up for each patient was calculated from  $\beta$ -blocker therapy initiation to the occurrence of the study end point, death from nonarrhythmic cause, the date of last visit, or the initiation of other treatments (ie, other antiarrhythmics or LCSD), whichever occurred first. All the analyses performed refer to patients treated exclusively with  $\beta$ -blockers; patients who initiated other antiarrhythmic treatments or underwent LCSD were censored from the analyses.

### Statistical Analysis

Statistical analysis was performed from April until August 2021 using R Software (version 3.6.0; The R Foundation for Statistical Computing). Data distribution was assessed using the 1-sided Kolmogorov-Smirnov test. Continuous data were reported as median and IQR and were compared using appropriate nonparametric tests. Categorical data were reported with frequencies and relative percentages and were

compared using the  $\chi^2$  test or the Fisher exact test. Bonferroni correction was applied to account for multiple comparisons. To quantify the risk of experiencing an LTAE while receiving  $\beta$ -blockers only, we used a Kaplan-Meier estimator of LTAE-free survival function with follow-up during  $\beta$ -blocker treatment as a timescale, and the approach proposed by Snapinn et al<sup>14</sup> to fit an extended standard Kaplan-Meier estimate stratified by time-varying type of principal  $\beta$ -blockers used.

Multivariable Cox proportional hazards model was used to evaluate the associations of history of LTAE before diagnosis of CPVT, occurrence of unexplained syncope before diagnosis of CPVT, variants in CPVT-enriched domains, and type of  $\beta$ -blocker therapy with the risk of experiencing an LTAE during  $\beta$ -blocker treatment. The type of  $\beta$ -blocker used was considered a time-dependent covariate to account for patients who switched or stopped  $\beta$ -blocker therapy. The use of propranolol and selective  $\beta$ -blockers (metoprolol, atenolol, bisoprolol, and nebivolol) was compared with nadolol, which is accepted as standard of care.<sup>6</sup> Periods without therapy were defined as time-lags of 1 week or more during which patients interrupted treatment and were excluded from the analysis. A robust sandwich estimator for the covariance matrix of the Cox regression coefficients was used to adjust for clustering caused by inclusion of members of the same family. A 2-sided *P* value less than .05 was considered significant.

## Results

### Cohort Composition

The study included 216 patients with RYR2 CPVT (121 of 216 female [55%], median [IQR] age 14, [9-30] years). Specifically, they were 120 probands (66 female patients [55%], median [IQR] age at diagnosis, 14.0 [10.0-20.5] years) and their 96 family members (55 female family members [57%]; median [IQR] age at diagnosis 18.0 [6.8-44.7] years). Interestingly, in 36 of 78 of probands (46%) the RYR2 variant was likely de novo.

### Baseline Characteristics

Table 1 summarizes baseline characteristics of the study population. Prior to diagnosis and initiation of treatment, 119 of 216 patients (55%) experienced CPVT-related arrhythmic symptoms, occurring at a median (IQR) age of 11.0 (7.5-15.4) years; 40 of 216 patients (19%) had survived an LTAE (24 [60%] female; median [IQR] age, 15.3 [11.1-25.1] years); and 101 of 216 patients (47%) had experienced an unexplained syncope. Importantly, 22 of 101 patients (22%) who had experienced a syncope also experienced an LTAE prior to the diagnosis of CPVT and starting treatment, with a median (IQR) lag between the syncope and the occurrence of LTAE of 1.8 (1.0-5.7) years.

All patients presented with a normal ECG (Table 1). Of the 177 of 216 patients (82%) for whom an arrhythmic evaluation prior to  $\beta$ -blocker therapy was available, 106 (60%) had a documentation of catecholamine-induced VT. In 59 of 106 patients (56%), bidirectional VT was documented (Figure 1A),

**Table 1. Demographic, Clinical, and Electrocardiographic Characteristics of the Study Population**

Characteristic	No. (%)
<b>Demographic</b>	
Probands	120 (56)
<b>Sex</b>	
Female	121 (56)
Male	95 (44)
<b>Age at therapy start, median (IQR), y</b>	
0-10	64 (30)
11-20	78 (36)
21-40	37 (17)
>40	37 (17)
<b>Arrhythmic symptoms prior to therapy</b>	
LTAE	40 (19)
Syncope	101 (47)
<b>Age at first arrhythmic symptom, median (IQR), y</b>	
Therapeutic delay, median (IQR), y	11 (8-15)
	2 (0.4-5.7)
<b>Electrocardiographic features, median (IQR)<sup>a</sup></b>	
HR, beats per minute	63 (54-80)
PR, ms	140 (120-153)
QRS, ms	80 (80-90)
QTc interval, ms	396 (379-418)
U wave, No./total No.	85/194 (44)
<b>Arrhythmic features, No./total No.<sup>b</sup></b>	
VT	106/177 (60)
VTns	77/106 (73)
VTs	29/106 (27)
Bidirectional morphology	59/106 (56)
<b>Type of <math>\beta</math>-blocker at the initiation of treatment</b>	
Nadolol	110 (51)
Propranolol	30 (14)
Selective	57 (26)
Other $\beta$ -blockers	19 (9)

Abbreviations: HR, heart rate; LTAE, life-threatening arrhythmic event; VT, ventricular tachycardia; VTns, nonsustained ventricular tachycardia.


<sup>a</sup> Data from 194 of 216 patients (90%) with an electrocardiogram available.

<sup>b</sup> Data from 177 of 216 patients (82%) with an arrhythmic assessment prior to therapy.

while in the remaining 47 of 119 cases (44%), only polymorphic VT (Figure 1B) was recorded.

### Identification of CPVT-Enriched RYR2 Domains

To identify mutational hotspots, we compared the distribution of 83 RYR2 missense variants that were identified in the probands (eTable 2 in the Supplement) with 1913 rare RYR2 variants in control individuals (eTable 3 in the Supplement). We found that the following were CPVT-enriched domains (see eMethods 2 in the Supplement): HD1 domain (residues 2110-2679; odds ratio [OR], 3.1; 95% CI, 1.8-5.1; *P* < .001), central domain (residues 3636-4030; OR, 4.0; 95% CI, 2.2-7.3; *P* < .001), U-motif domain (residues 4091-4207; OR, 10.0; 95% CI, 4.5-22.4; *P* < .001), S2 domain (residues 4570-4594; OR, 9.4; 95% CI, 1.8-49.3; *P* = .001), S6 domain (residues 4836-4888; OR, 15.8; 95% CI, 2.6-95.4; *P* < .001), and C-terminal

Figure 1. Typical Electrocardiographic Manifestations of *RYR2* Catecholaminergic Polymorphic Ventricular Tachycardia (VT)

Example of ventricular arrhythmias elicited by exercise in 2 different patients (1 male, 1 female) with 2 different missense *RYR2* variants (p.M4728A and p.R4822L). Findings of the basal electrocardiogram are normal, but exercise progressively induces the appearance of ventricular arrhythmias with increasing complexity. Ventricular arrhythmias usually start as isolated premature ventricular complexes, organizing into bigeminy and couplets (exercise 1 minute), followed by the appearance of VT with a bidirectional (A) or polymorphic (B) morphology. The interruption of exercise leads to the gradual resolution of arrhythmias in the inverse order of appearance (recovery 1 minute).

domain (CTD) (residues 4889-4969; OR, 9.6; 95% CI, 3.0-31.4;  $P < .001$ ; Figure 2; eFigure and eTable 3 in the Supplement).

### Outcome During $\beta$ -Blocker Treatment

All patients received  $\beta$ -blockers only (Table 1) and were followed up for a mean (SD) of 9.4 (7.5) years. Of them, 28 of 216 patients (13%) experienced an LTAE during  $\beta$ -blocker therapy only, corresponding to annual rate of LTAE of 1.9% (95% CI, 1.3%-2.7%). Relevantly, 12 of 28 (43%) had already survived an LTAE prior to diagnosis and in the absence of therapy, while the remaining 16 (57%) experienced their first LTAE during treatment with  $\beta$ -blocker. As shown in Figure 3A, the cumulative probability of experiencing an LTAE while treated with  $\beta$ -blocker therapy only was 2.4% (95% CI, 0.3%-4.5%), 9.3% (95% CI, 4.8%-13.6%), and 20.8% (95% CI, 12.9%-28.0%) at 1, 5, and 10 years of follow-up, respectively.

Of the 28 individuals who experienced an LTAE while taking  $\beta$ -blockers only, 18 (64%) had an ICD when the LTAE occurred and all survived. Of the remaining 10 patients who were not carriers of an ICD, 4 (40%) died suddenly (eTable 4 in the Supplement), 4 (40%) were rescued by external defibrillation, while 2 patients (20%) experienced a hemodynamically unstable fast polymorphic VT, which terminated spontaneously. Overall, the probability that an LTAE resulted in a fatal outcome was higher in patients without an ICD (4 of 10 [40%] died) as compared with patients with an ICD implanted (0 of 18 died;  $P = .01$ ). A total of 7 of 24 patients (29%) surviving a first LTAE had multiple LTAEs during their life (median [IQR], 3 [2-7]).

### Factors Associated With the Occurrence of an LTAE During $\beta$ -Blocker Treatment


Multivariable analysis (Table 2) demonstrated that history of LTAE before diagnosis (hazard ratio [HR], 3.3; 95% CI, 1.2-

8.9;  $P = .02$ ) and unexplained syncope before diagnosis (HR, 4.5; 95% CI, 1.8-11.1;  $P = .001$ ), as well as C-terminal domain variants (HR, 18.1; 95% CI, 4.1-80.8;  $P < .001$ ) were independent predictors for LTAE occurrence during  $\beta$ -blocker treatment only. Importantly, selective  $\beta$ -blockers (LTAE rate 4.0% per year; 95% CI, 2.2%-6.6%) were associated with a 6-fold increase of LTAE risk (HR, 5.8; 95% CI, 2.1-16.3;  $P = .001$ ) as compared with nadolol (LTAE rate 0.8% per year; 95% CI, 0.3%-1.6%; Figure 3B). Conversely, propranolol (LTAE rate 2.1% per year; 95% CI, 0.4%-6.3%) use was not associated with a significant increase in risk as compared with nadolol (HR, 1.8; 95% CI, 0.4-7.3;  $P = .44$ ; Figure 3B). C statistics confirmed that the model performed well (C statistic = 0.81; 95% CI, 0.72-0.91) and sensitivity analysis in probands confirmed the results of the multivariable analysis (eTable 5 in the Supplement).

### Defining the Role of the ICD in Patients With CPVT


Globally, 79 of 216 patients (37%) received an ICD (46 of 79 patients [58%] female; median [IQR] age at implant, 16.0 [13.1-28.4] years), with 33 of 79 patients (42%) being implanted in secondary prevention of SCD. Over a median (IQR) 7.5 (3.7-12.6) years of follow-up, 21 of 79 patients (27%) experienced an LTAE that triggered an appropriate ICD shock (LTAE rate 4.1% per year; 95% CI, 2.5%-6.3%). ICD successfully terminated the LTAE in 18 of 21 cases (86%). Overall, all 15 episodes of VT were successfully interrupted, while only 3 of 6 episodes (50%) of hemodynamically unstable, polymorphic fast VT were terminated ( $P < .001$ ). Furthermore, complications requiring surgical revision occurred in 14 of 79 patients (17%) (2.6% per year; 95% CI, 1.4%-4.3%), while 12 patients (15%) (2.0% per year; 95% CI, 1.1%-3.6%) experienced inappropriate shocks (eTable 6 in the Supplement). Importantly, no inappropriate shock triggered an LTAE, and overall, the benefit of ICD implant outweighed the harm (eTable 7 in the Supplement).

**Figure 2. Distribution of Patients With and Without Life-Threatening Arrhythmic Events (LTAEs) During  $\beta$ -Blocker Treatment Only According to the Location of *RYR2* Variants on the Amino Acid Sequence**



The figure represents the amino acid sequence of *RYR2* protein, divided into the different domains identified by Dhindwal et al.<sup>10</sup> The length of each domain is proportional to the number of amino acids that compose the domain. Amino acids that are not localized to any domain are grouped and represented separately on the right-hand side. Columns above each *RYR2* domain represent the number of patients with variants localized in that specific domain. Blue shows the proportion of patients without LTAE during  $\beta$ -blocker treatment, while orange shows the proportion of patients with LTAE during  $\beta$ -blocker treatment only. As shown by the multivariable analysis, patients with variants in the C-terminal domain (CTD; amino acids 4889-4969) were at increased risk of experiencing an LTAE during  $\beta$ -blocker treatment only.

Figure 3. Clinical Course of Patients With *RYR2* Catecholaminergic Polymorphic Ventricular Tachycardia During  $\beta$ -Blocker Therapy Only



A, Kaplan-Meier estimate of cumulative survival free from the first life-threatening arrhythmic events (LTAEs) in  $\beta$ -blocker therapy only shows the cumulative probability of experiencing a first catecholaminergic polymorphic ventricular tachycardia while taking  $\beta$ -blocker therapy was 2.4% (95% CI, 0.3%-4.5%), 9.3% (95% CI, 4.8%-13.6%), and 20.8% (95% CI, 12.9%-28.0%) at 1, 5, and 10 years of follow-up, respectively. B, Kaplan-Meier estimate of cumulative survival free from the first LTAE stratified by time-varying type of principal  $\beta$ -blocker used demonstrates that the cumulative probability of experiencing a first LTAE while taking  $\beta$ -blocker therapy only was 26.2% (95% CI, 9.7%-39.8%), 10.0% (95% CI, 0.0%-22.9%), and 1.0% (95% CI, 0%-3.0%) at 5 years of follow-up for selective  $\beta$ -blockers, propranolol, and nadolol, respectively.

Table 2. Factors Associated With the Occurrence of First LTAE During  $\beta$ -Blocker Therapy According to Multivariable Cox Regression in 216 Patients With *RYR2*-Related CPVT<sup>a</sup>

Factor	No. of patients	No. of events per person-year	Rate per 100 person-years (95% CI)	HR (95% CI)	P value
Episode of life-threatening arrhythmias before diagnosis					
No	176	16/1225	1.3 (0.7-2.1)	1 [Reference]	NA
Yes	40	12/262	4.6 (2.4-8.0)	3.3 (1.2-8.9)	.02
Episode of unexplained syncope before diagnosis					
No	115	5/814	0.6 (0.2-1.4)	1 [Reference]	NA
Yes	101	23/674	3.4 (2.2-5.1)	4.5 (1.8-11.1)	.001
Variant location					
Not CPVT-enriched domains	94	9/495	1.8 (0.8-3.5)	1 [Reference]	NA
HD1 domain	71	8/621	1.3 (0.6-2.5)	1.0 (0.3-3.0)	.97
Central domain	20	5/128	3.9 (1.3-9.1)	1.6 (0.5-5.4)	.47
U-motif domain	16	3/102	2.9 (0.6-8.6)	2.1 (0.6-7.1)	.22
S2 domain	2	0/14	0 (0-26.3)	NA	NA
S6 domain	8	0/105	0 (0-3.5)	NA	NA
C-terminal domain	5	3/23	13.0 (2.7-38.1)	18.1 (4.1-80.8)	<.001
Therapy (time-dependent) <sup>b</sup>					
Nadolol <sup>c</sup>	NA	7/880	0.8 (0.3-1.6)	1 [Reference]	NA
Propranolol <sup>d</sup>	NA	3/140	2.1 (0.4-6.3)	1.8 (0.4-7.3)	.44
Selective <sup>e</sup>	NA	15/358	4.2 (2.3-6.9)	5.8 (2.1-16.3)	.001

Abbreviations: CPVT, catecholaminergic polymorphic ventricular tachycardia; HR, hazard ratio; LTAE, life-threatening arrhythmic event; NA, not applicable.

<sup>a</sup> The outcome is the occurrence of a first life-threatening arrhythmic event (LTAE) during  $\beta$ -blocker therapy only.

<sup>b</sup> Additionally in other  $\beta$ -blockers: 3 events in 109 person-years of observation.

<sup>c</sup> The daily dosage (median [IQR]) of nadolol was 1.0 (0.7-1.2) mg/kg.

<sup>d</sup> The daily dosage (median [IQR]) of propranolol was 2.0 (1.4-3.2) mg/kg.

<sup>e</sup> The most used drugs were atenolol and metoprolol, at median (IQR) daily dosage of 0.9 (0.6-2.0) mg/kg and 1.4 (1.0-2.3) mg/kg, respectively.

## Discussion

CPVT is a potentially fatal genetic arrhythmia syndrome, but 20 years after the identification of *RYR2* as the main causative gene,<sup>2,15</sup> an important delay between the first clinical manifestation and the diagnosis persists. In our cohort of 216 patients with *RYR2* CPVT who were followed

up prospectively, half of patients who were not diagnosed after an unexplained syncope also experienced an LTAE before CPVT was recognized. Moreover, despite  $\beta$ -blocker therapy, approximately 15% of patients experienced LTAEs. The challenge for the clinician is, therefore, 2-fold: first, to timely diagnose a patient and start  $\beta$ -blocker therapy, and then, to identify patients at a high risk of  $\beta$ -blocker failure.

### Not All $\beta$ -Blockers Are Equally Protective in Patients With CPVT

Nadolol, a powerful  $\beta$ -blocker with a long half-life, is preferred by the experts in the field. Although it reduces the arrhythmic burden in patients with CPVT,<sup>16</sup> we observed that 25% of LTAEs in patients treated with  $\beta$ -blockers only occurred in nadolol. Furthermore, owing to its limited availability in many countries worldwide,<sup>6</sup> a clinical need for an evidence-based appraisal of alternative  $\beta$ -blockers exists.

Our data demonstrated that commonly used selective  $\beta$ -blockers are associated with a particularly high risk of LTAE (4.0% per year) in patients with CPVT, and they may be used only in case of nonselective  $\beta$ -blocker intolerance or unavailability. Conversely, our data suggest that propranolol might be an alternative to nadolol, where the latter is unavailable. A word of caution must be spent on the dosing regimen of standard-release propranolol (3-4 administrations daily), which might favor poor adherence. In some countries, long-acting formulation of propranolol is available but since both the area under the plasma concentration-time curve and the peak concentration are significantly lower than following identical doses of standard-release propranolol,<sup>17</sup> it should not be considered a simple milligram-for-milligram substitute for standard-release propranolol,<sup>18</sup> and higher doses of long-acting propranolol may need to be used.

### Clinical Factors Associated With $\beta$ -Blocker Failure

We provide factors identifying patients at increased LTAE risk during  $\beta$ -blocker therapy. Specifically, patients with CPVT-related symptoms before diagnosis (LTAE or an unexplained syncope) should be regarded at high risk for  $\beta$ -blocker failure.

Akin to other hereditary arrhythmogenic diseases, such as Brugada syndrome,<sup>19</sup> or long QT syndrome (LQTS),<sup>20</sup> survivors of LTAE have a poorer outcome at follow-up, with recurrence rate during  $\beta$ -blocker therapy of 5.8% per year. Importantly, survivors of LTAE in CPVT have a significantly higher recurrence rate than LTAE survivors with LQTS (2.0% per year).<sup>20</sup>

At variance with previous evidence,<sup>5</sup> our data highlight how important syncope is in CPVT, both for diagnosis and prognosis. Exercise- or emotion-induced syncope is frequently the first symptom of CPVT, and in one-fifth of patients is a harbinger of an avoidable LTAE: half of patients who experienced an LTAE before diagnosis had experienced a syncope 2 years prior. More importantly, we demonstrate that syncope is also a useful factor associated with  $\beta$ -blocker therapy failure. In light of this evidence, awareness about exercise- or emotion-related syncope as an ominous clue of a potentially lethal genetic condition should be raised not only among cardiologists but especially among emergency medicine specialists, pediatricians, and general practitioners. Prompt referral to an expert tertiary center would reduce the diagnostic delay but, in our cohort, would have prevented half of cardiac arrests prior to diagnosis.

### Genotype Factors

The *RYR2* gene is one of the largest human genes and the attribution of a pathogenic role to a rare variant is challenging,<sup>21</sup> given the high rate of rare but benign variants: it is estimated

that 3.2% of healthy control individuals carry them.<sup>22</sup> Our data suggest that CPVT-causing variants are not randomly distributed, but cluster in functionally relevant domains.<sup>23</sup> Identification of these hotspots is important when dealing with a rare variant, aiding in distinguishing causative variants from background noise.

In analogy with what we identified in patients with LQTS, we demonstrate that genetic substrate modulates  $\beta$ -blocker therapy response.<sup>24</sup> Crucially, we showed that patients with *RYR2* variants affecting the C-terminal domain (CTD, amino acids 4889-4969) were at higher risk of  $\beta$ -blocker failure, independently of clinical presentation and  $\beta$ -blocker type used (Figure 2). CTD is highly conserved<sup>25</sup> and plays a fundamental role in the channel function. Functional studies on skeletal isoform (*RYR1*) have identified that 3 activating ligands ( $\text{Ca}^{2+}$ , ATP, and caffeine) bind to different interdomain interfaces of the CTD,<sup>26</sup> suggesting a pivotal role in the channel gating. Recent data reinforced this hypothesis, demonstrating that *RYR2* variants affecting the CTD alter electrostatic interactions critical for the maintenance of the channel's closed state, resulting in a reduced threshold for arrhythmogenic spontaneous  $\text{Ca}^{2+}$  release.<sup>23</sup>

### ICD in CPVT

Malignancy of CPVT has led to the proposal for other treatments, such as flecainide and LCSD. However, survival data on flecainide are missing, while LCSD is burdened by arrhythmic recurrences in one-third of patients.<sup>27</sup> ICD has represented the bastion of protection against LTAE for patients with CPVT. Accordingly, we found that ICD confers a significant survival benefit in patients with CPVT treated with  $\beta$ -blocker. Our observation sharply departs from the data by Van der Werf et al,<sup>7</sup> who failed in identifying such a benefit in survivors of cardiac arrest with CPVT. In their cohort, over approximately 5 years of follow-up, SCD occurred in 3 of 79 patients (4%) with an ICD. However, the authors do not provide compelling evidence to define whether an ICD-induced proarrhythmic event caused the death, as in one case no information on medication was available; in the second, the patient was treated with combination of drugs, including verapamil and amiodarone, which may be pro-arrhythmic in their own right, or as suggested by authors themselves raised the defibrillation threshold; while in the third patient, sudden death occurred but the ICD was not interrogated. Naturally, the choice of ICD should be carefully weighted, as complications requiring surgical revision occurred in 17% of patients, but this notwithstanding, in our experience, the benefits of ICD implant still outweigh the harms, especially in survivors of LTAE, and we advocate for its continued use in high-risk patients with CPVT.

### Limitations

A prospective cohort study focusing on  $\beta$ -blocker therapy only is subject to the inherent limitations of such an analysis. Previous randomized clinical trials were unable to recruit enough patients for the assessment of a clinically relevant end point,<sup>28</sup> supporting the view that nonrandomized data may represent the best source of evidence for relatively rare conditions such as CPVT.

## Conclusions

In this cohort study of patients with *RYR2*-related CPVT, selective  $\beta$ -blockers were associated with a higher risk of LTAE

as compared with nadolol. Patients who have survived an LTAE and/or experienced an unexplained syncope prior to diagnosis, as well as carriers of variants located in the CTD of *RYR2*, were at higher risk of  $\beta$ -blocker failure. ICD was associated with reduced mortality in patients with high-risk CPVT.

### ARTICLE INFORMATION

**Accepted for Publication:** February 2, 2022.

**Published Online:** March 30, 2022.  
doi:10.1001/jamacardio.2022.0219

**Author Affiliations:** Department of Molecular Cardiology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy (Mazzanti, Kukavica, Trancuccio, Memmi, Bloise, Gambelli, Marino, Morini, Monteforte, Napolitano, Priori); Department of Molecular Medicine, University of Pavia, Pavia, Italy (Mazzanti, Kukavica, Trancuccio, Napolitano, Priori); ERN Guard-Heart European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (Mazzanti, Napolitano, Priori); Department of Molecular Cardiology, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (Mazzanti, Kukavica, Trancuccio, Santiago, Priori); Health in Code, A Coruña, Spain (Ortiz-Genga, Monserrat); Department of Cardiology, ARNAS Civico Cristina Di Benefratelli, Palermo, Italy (Giordano); Department of Electrophysiology, Hospital Privado Del Sur, Buenos Aires, Argentina (Keegan); Department of Cardiology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy (Tomas); Unit of Inherited and Rare Cardiovascular Diseases, Onassis Cardiac Surgery Center, Athens, Greece (Anastasakis); Department of Cardiology, The Royal Children's Hospital, Melbourne, Australia (Davis); Department of Pediatrics, University of Melbourne, Melbourne, Australia (Davis); Murdoch Children's Research Institute, Melbourne, Australia (Davis); Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan (Shimizu); Department of Pediatric Cardiology, University of Leiden, Leiden, the Netherlands (Blom).

**Author Contributions:** Drs Priori and Mazzanti had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Mazzanti, Giordano, Keegan, Anastasakis, Priori.

**Acquisition, analysis, or interpretation of data:** Mazzanti, Kukavica, Trancuccio, Memmi, Bloise, Gambelli, Marino, Ortiz-Genga, Morini, Monteforte, Tomasi, Davis, Shimizu, Blom, Santiago, Napolitano, Monserrat, Priori.

**Drafting of the manuscript:** Mazzanti, Kukavica, Trancuccio, Memmi, Gambelli, Marino, Morini.  
**Critical revision of the manuscript for important intellectual content:** Mazzanti, Bloise, Ortiz-Genga, Monteforte, Giordano, Keegan, Tomasi, Anastasakis, Davis, Shimizu, Blom, Santiago, Napolitano, Monserrat, Priori.  
**Statistical analysis:** Mazzanti, Kukavica, Trancuccio, Giordano, Priori.

**Obtained funding:** Priori.

**Administrative, technical, or material support:** Mazzanti, Kukavica, Trancuccio, Memmi, Gambelli, Marino, Tomasi, Monserrat.  
**Supervision:** Mazzanti, Napolitano.

**Conflict of Interest Disclosures:** Dr Ortiz-Genga reported personal fees from Health in Code during the conduct of the study. Drs Priori and Napolitano

reported an issued patent for a method of gene transfer for the treatment of recessive catecholaminergic polymorphic ventricular tachycardia, negotiation for licensing ongoing by the Istituti Clinici Scientifici Maugeri, Società per Azioni, Società Benefit (inventors Drs Priori, Mazzanti, and Napolitano) report a pending patent for compositions and methods for the treatment of dominantly-inherited catecholaminergic polymorphic ventricular tachycardia, and negotiation for licensing (20210030894). Dr Monserrat reported personal fees from Bristol Myers Squibb, and is a shareholder of Dilemma Solutions SL and Health in Code. No other disclosures were reported.

**Funding/Support:** Dr Priori reports support from Ricerca Corrente funding scheme of the Italian Ministry of Health and Italian Ministry of Research and University Dipartimenti di Eccellenza 2018 to 2022 grant to the Molecular Medicine Department (University of Pavia).

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

### REFERENCES

- Coumel P, Fidelle J, Lucet V, Attuel P, Bouvrain Y. Catecholamine-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases. *Heart*. 1978;40:28-37.
- Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (*hRyR2*) underlie catecholaminergic polymorphic ventricular tachycardia. *Circulation*. 2001;103(2):196-200. doi:10.1161/01.CIR.103.2.196
- Laitinen PJ, Brown KM, Piippo K, et al. Mutations of the cardiac ryanodine receptor (*RyR2*) gene in familial polymorphic ventricular tachycardia. *Circulation*. 2001;103(4):485-490. doi:10.1161/01.CIR.103.4.485
- Priori SG, Blomström-Lundqvist C, Mazzanti A, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J*. 2015;36(4):2793-2867. doi:10.1093/eurheartj/ehv316
- Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. *Circulation*. 2009;119(18):2426-2434. doi:10.1161/CIRCULATIONAHA.108.829267
- Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular

tachycardia: are all beta-blockers equivalent? *Heart Rhythm*. 2017;14(1):e41-e44. doi:10.1016/j.hrthm.2016.09.012

7. van der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. *Eur Heart J*. 2019;40(35):2953-2961. doi:10.1093/eurheartj/ehz309

8. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424. doi:10.1038/gim.2015.30

9. Sun B, Yao J, Ni M, et al. Cardiac ryanodine receptor calcium release deficiency syndrome. *Sci Transl Med*. 2021;13(579):eaba7287. doi:10.1126/scitranslmed.aba7287

10. Dhindwal S, Lobo J, Cabra V, et al. A cryo-EM-based model of phosphorylation-and FKBP12.6-mediated allosterism of the cardiac ryanodine receptor. *Sci Signal*. 2017;10(480):eaai8842. doi:10.1126/scisignal.aai8842

11. Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. *J Am Coll Cardiol*. 2011;57(23):2317-2327. doi:10.1016/j.jacc.2010.12.036

12. Olubando D, Hopton C, Eden J, et al. Classification and correlation of *RYR2* missense variants in individuals with catecholaminergic polymorphic ventricular tachycardia reveals phenotypic relationships. *J Hum Genet*. 2020;65(6):531-539. doi:10.1038/s10038-020-0738-6

13. Mazzanti A, Guz D, Trancuccio A, et al. Natural history and risk stratification in Andersen-Tawil syndrome type 1. *J Am Coll Cardiol*. 2020;75(15):1772-1784. doi:10.1016/j.jacc.2020.02.033

14. Snappin SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. *Am Stat*. 2005;59(4):301-307. doi:10.1198/000313005X70371

15. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. *Am J Hum Genet*. 2001;69(6):1378-1384. doi:10.1086/324565

16. Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with  $\beta$ 1-selective  $\beta$ -blockers in patients with catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*. 2016;13(2):433-440. doi:10.1016/j.hrthm.2015.09.029



17. Garg DC, Jallad NS, Mishriki A, et al. Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol. *J Clin Pharmacol*. 1987;27(5):390-396. doi:10.1002/j.1552-4604.1987.tb03036.x
18. Mishriki AA, Weidler DJ. Long-acting propranolol (inalderal LA): pharmacokinetics, pharmacodynamics and therapeutic use. *Pharmacotherapy*. 1983;3(6):334-341. doi:10.1002/j.1875-9114.1983.tb03294.x
19. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. *Circulation*. 2010;121(5):635-643. doi:10.1161/CIRCULATIONAHA.109.887026
20. Mazzanti A, Maragna R, Vacanti G, et al. Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. *J Am Coll Cardiol*. 2018;71(15):1663-1671. doi:10.1016/j.jacc.2018.01.078
21. Priori SG, Mazzanti A, Santiago DJ, Kukavica D, Tranuccio A, Kovacic JC. Precision medicine in catecholaminergic polymorphic ventricular tachycardia: JACC Focus Seminar 5/5. *J Am Coll Cardiol*. 2021;77(20):2592-2612. doi:10.1016/j.jacc.2020.12.073
22. Kapplinger JD, Pundi KN, Larson NB, et al. Yield of the RYR2 genetic test in suspected catecholaminergic polymorphic ventricular tachycardia and implications for test interpretation. *Circ Genom Precis Med*. 2018;11(2):e001424. doi:10.1161/CIRCGEN.116.001424
23. Guo W, Wei J, Estillore JP, et al. RyR2 disease mutations at the C-terminal domain intersubunit interface alter closed-state stability and channel activation. *J Biol Chem*. 2021;297(1):100808. doi:10.1016/j.jbc.2021.100808
24. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. *JAMA*. 2004;292(11):1341-1344. doi:10.1001/jama.292.11.1341
25. Meissner G. The structural basis of ryanodine receptor ion channel function. *J Gen Physiol*. 2017;149(12):1065-1089. doi:10.1085/jgp.201711878
26. des Georges A, Clarke OB, Zalk R, et al. Structural basis for gating and activation of RyR1. *Cell*. 2016;167(1):145-157.e17. doi:10.1016/j.cell.2016.08.075
27. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. *Circulation*. 2015;131(25):2185-2193. doi:10.1161/CIRCULATIONAHA.115.015731
28. Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. *JAMA Cardiol*. 2017;2(7):759-766. doi:10.1001/jamacardio.2017.1320